SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was
superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic
breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected
chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.